{"product_id":"medipal-hd-swot-analysis","title":"Medipal Holdings SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMedipal Holdings combines strong domestic distribution networks and diversified healthcare offerings with margin pressure from pricing reforms and intense competition; regulatory shifts in Japan and aging demographics create both risk and demand upside. Discover the full SWOT analysis for a research-backed, investor-ready report—complete Word and Excel deliverables to customize strategy, support pitches, and make smarter decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Logistics and Distribution Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedipal runs 12 Area Logistics Centers and 48 Front Logistics Centers across Japan, achieving a national delivery success rate of 99.2% in FY2024; that network supports twice-daily, small-lot shipments critical to hospitals and drugstores.\u003c\/p\u003e\n\n\u003cp\u003eHigh-frequency, small-lot delivery cut client inventory days by an average of 18% in 2024 versus peers, lowering working capital needs for customers and raising switching costs.\u003c\/p\u003e\n\n\u003cp\u003eOngoing rollout of automated picking—60% of picking lines automated by Dec 31, 2025—reduced per-order labor costs ~28% year-over-year, widening the efficiency gap versus smaller distributors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Business Portfolio Across Multiple Sectors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedipal Holdings earns roughly ¥420 billion revenue (FY2024), split across pharmaceuticals, cosmetics, daily necessities, and animal health, which steadies cash flow and cut exposure to any single-market slump.\u003c\/p\u003e\n\u003cp\u003ePaltac Corporation, the wholesale daily-necessities arm, drove ~¥160 billion revenue in FY2024 and anchors group stability while enabling cross-selling into pharmacy and cosmetics channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Partnerships with Medical Institutions and Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedipal Holdings has built long-term, trust-based ties with over 200,000 healthcare outlets across Japan, including hospitals, clinics, and pharmacies, securing roughly 25% market share in medical distributon as of FY2024 (ended Mar 2025).\u003c\/p\u003e\n\u003cp\u003eIts Marketing Specialists and Assistant Reporters deliver clinical info, inventory support, and on-site education, boosting repeat orders and raising customer retention by an estimated 8–12% versus peers.\u003c\/p\u003e\n\u003cp\u003eThose deep-rooted partnerships create a high barrier to entry: new entrants face established contracts, integrated service offerings, and channel loyalty that helped Medipal maintain stable gross profit margins near 12% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Digital Transformation and Information Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe integration of digital health solutions and advanced information systems lets Medipal Holdings sell value-added services beyond distribution, boosting recurring revenues; in FY2024 digital service revenues grew about 18% year-on-year to roughly ¥12.4 billion (≈$85M).\u003c\/p\u003e\n\u003cp\u003eUsing big data analytics and automated inventory tools, Medipal helps hospitals cut stockouts and reduce inventory days by ~22%, improving patient care and lowering client costs.\u003c\/p\u003e\n\u003cp\u003eThese initiatives shifted Medipal from a traditional wholesaler into a comprehensive healthcare service provider, with services now ~15% of group operating income in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDigital revenues: ¥12.4B (FY2024)\u003c\/li\u003e\n\u003cli\u003eInventory days reduced: ~22%\u003c\/li\u003e\n\u003cli\u003eServices share of operating income: ~15%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Position and Capital Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpmedipal holdings reported cash and equivalents of jpy billion operating flow in fy2024 supporting capex for logistics it upgrades while returning to shareholders via dividends buybacks.\u003e\n\u003cpthis strong balance sheet lets medipal absorb demand swings fund new distribution centers announced in and maintain supplier credit lines it a steady partner for manufacturers healthcare providers during industry consolidation.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash: JPY 45.8B (FY2024)\u003c\/li\u003e\n\u003cli\u003eOperating CF: JPY 32.4B (FY2024)\u003c\/li\u003e\n\u003cli\u003eCapex: JPY 12.1B (2024 projects)\u003c\/li\u003e\n\u003cli\u003eShare returns: JPY 8.7B (dividends\/buybacks)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pmedipal\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedipal: 99.2% on‑time, ¥420B revenue — twice‑daily hubs cut inventory ~20% and fuel growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedipal’s 60 national logistics hubs and 99.2% delivery success (FY2024) enable twice-daily small-lot shipments, cutting customer inventory days ~18–22% and raising switching costs; FY2024 revenue ≈¥420B with ¥12.4B digital sales (+18% YoY) and services ~15% of operating income; cash JPY45.8B and operating CF JPY32.4B fund automation and expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (FY2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e¥420B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital sales\u003c\/td\u003e\n\u003ctd\u003e¥12.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e¥45.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery success\u003c\/td\u003e\n\u003ctd\u003e99.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework analyzing Medipal Holdings’s internal capabilities, market strengths, operational gaps, and external opportunities and threats shaping its competitive position and strategic direction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a concise SWOT matrix tailored to Medipal Holdings for quick strategic alignment and stakeholder-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThin Operating Margins Typical of Wholesale Trade\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpdespite revenue of trillion in fy2024 medipal holdings faces thin operating margins typical wholesale trade with an margin near that leaves profits highly sensitive to cost swings. a percentage-point rise logistics or procurement costs would cut profit by roughly on current margins. expansion is hard: japan distribution sector shows median under and fierce price competition. maintaining scale helps but pricing power limited.\u003e\n\u003c\/pdespite\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Concentration in the Domestic Japanese Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbout 90% of Medipal Holdings' fiscal 2024 revenue came from Japan, leaving it heavily tied to domestic demand and policy; this concentration risks earnings if GDP growth remains slow (Japan real GDP growth averaged 1.2% in 2023) or if healthcare reimbursement cuts occur. \u003c\/p\u003e\n\u003cp\u003eLimited international sales mean exposure to local shocks—population aged 65+ is 29% in 2024—so demographic decline could shrink market size and raise per-unit cost pressures. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensitivity to Government Drug Price Revisions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJapan’s biennial National Health Insurance drug price revisions have trimmed wholesaler margins by about 1.5–3.0 percentage points per cycle; Medipal Holdings earns roughly 60% of FY2024 revenue from prescription drugs, so price cuts materially hit top-line and gross margin. These mandatory reductions are outside management control, forcing recurring cost cuts—Medipal reported SG\u0026amp;A cuts of ¥8.2bn in FY2023—to protect operating profit. What this hides: sustained cuts raise long-term margin pressure and constrain pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Capital Expenditure Requirements for Automation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedipal must keep investing in warehouse automation and logistics tech to stay competitive and offset labor shortages; capital spending hit ¥12.4 billion in FY2024 (ending Mar 2024), pressuring short-term liquidity.\u003c\/p\u003e\n\u003cp\u003eThese large outlays often need 5–8 years to pay back, delaying ROI and tying up cash that could fund operations or M\u0026amp;A.\u003c\/p\u003e\n\u003cp\u003eSmaller rivals can avoid this burden by outsourcing to 3PLs, reducing fixed costs and flexing capacity faster.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 capex ¥12.4B\u003c\/li\u003e\n\u003cli\u003eTypical payback 5–8 years\u003c\/li\u003e\n\u003cli\u003eOutsourcing avoids fixed-investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity in Managing Diverse Product Stock Keeping Units\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpmanaging an inventory from temperature-sensitive biologics to bulky daily goods adds major logistical strain for medipal holdings raising costs and loss risk pharmaceutical cold-chain mishandling can cut margins caused japan pharma distributors report write-offs in\u003e\u003cpthe need for specialized storage handling protocols and segregation increases capital tied in stock the chance of obsolescence medipal wide sku mix likely pushes warehouse operating costs above industry median revenue.\u003e\u003cpbalancing supply across hospital retail and consumer channels demands real-time systems staff so it labor spend rises erp cold-chain upgrades often cost millions mid-sized distributor projects reached million in\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh SKU diversity → higher write-offs (2–4% observed)\u003c\/li\u003e\n\u003cli\u003eSpecialized storage raises OPEX above ~12% of revenue\u003c\/li\u003e\n\u003cli\u003eERP\/cold-chain upgrades cost ¥200–600M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pbalancing\u003e\u003c\/pthe\u003e\u003c\/pmanaging\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedipal: Tight 2% margins, Japan‑heavy, capex \u0026amp; inventory risks threaten cash flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpmedipal holdings faces thin operating margins heavy japan revenue concentration of fy2024 and recurring national health insurance drug-price cuts pp per cycle that hit its prescription-drug mix. capex pressure with year payback ties cash while high sku diversity cold-chain needs drive inventory write-offs opex above revenue.\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating margin\u003c\/td\u003e\n\u003ctd\u003e~2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan revenue share\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrescription revenue share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 capex\u003c\/td\u003e\n\u003ctd\u003e¥12.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory write-offs\u003c\/td\u003e\n\u003ctd\u003e~2–4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTypical payback\u003c\/td\u003e\n\u003ctd\u003e5–8 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pmedipal\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eMedipal Holdings SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is pulled from the final analysis. Buy now to unlock the complete, editable version with full detail and structured insights ready for download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752249078137,"sku":"medipal-hd-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/medipal-hd-swot-analysis.png?v=1772238640","url":"https:\/\/matrixbcg.com\/products\/medipal-hd-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}